Odesa Criteria 2026: tests for autoimmune pancreatitis diagnosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This ambispective observational study evaluates the diagnostic performance of the Odesa Criteria 2026 (OC26), a domain-based point scoring system for autoimmune pancreatitis. It analyzes how well OC26 works across clinical, serological, imaging, and histology data in real-world patients. The study uses both retrospective and prospective data to determine sensitivity, specificity, predictive values, and interobserver agreement, aiming to support routine use and guideline development. No interventions are performed; participants are assessed using existing data to score OC26. The investigation is conducted at the Military Medical Clinical Center of the Southern Region in Odesa, Ukraine.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults (≥18 years) undergoing evaluation for suspected autoimmune pancreatitis.
* Availability of clinical, serological, imaging, and/or histological data required for OC26 scoring.
* Ability to provide informed consent (for prospective participants).

Exclusion Criteria:

* Confirmed alternative diagnosis explaining pancreatic findings (e.g., pancreatic cancer, acute pancreatitis of other etiology).
* Incomplete diagnostic data preventing OC26 scoring.
* Prior pancreatic surgery altering diagnostic interpretation.

Where it's running

• Military Medical Clinical Center of the Southern Region
  Odesa, Ukraine Recruiting
• Military Medical Clinical Center of the Southern Region
  Odesa, Ukraine Recruiting

Study contacts

• Principal investigator: Oleg Dovbenko — Odesa Regional Clinical Medical Center
• Study coordinator: Oleg Dovbenko, MD, PhD
• Email: dovbenko2015@hotmail.com
• Phone: +380682539685

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Blood protein biomarkers to help diagnose pancreatic cancer in adults

  This study tests whether blood protein biomarkers can help detect pancreatic ductal adenocarcinoma and tell it apart from chronic pancreatitis and mucinous pancreatic lesions, and whether combining markers with CA 19-9 improves accuracy.

  Recruiting Grigore T. Popa University of Medicine and Pharmacy · Iași · NCT07875582

• AI-guided decision support for managing pancreatic conditions

  This project will test an AI tool that reads contrast-enhanced CT scans to help doctors decide whether people with suspected pancreatic disease need surgery, close monitoring, or routine follow-up.

  Recruiting Changhai Hospital · Shanghai · NCT07439757

• Using AI for early screening of pancreatic cancer

  This study is testing if using artificial intelligence can help find pancreatic cancer earlier in people who are at high risk, like those with new diabetes or family history of the disease.

  Recruiting Changhai Hospital · Shanghai · NCT04743479

• Collecting medical information and tissue samples from patients with pancreatic disorders

  This study is collecting medical information and samples from people with pancreatic cancer or other pancreatic disorders to help find better ways to detect and treat these diseases.

  Recruiting at 3 sites Mayo Clinic · Phoenix, Arizona and 2 other locations · NCT00830557

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• Using contrast-enhanced ultrasound to check for local pancreatic cancer recurrence after surgery

  This pilot test uses contrast-enhanced ultrasound to see if it can help detect return of pancreatic cancer after surgery in patients being watched with CT scans.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07910383

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.